Key clinical point: Locally injected onabotulinumtoxinA could be a novel treatment option for major depressive disorder (MDD), devoid of the systemic effects of conventional antidepressants.
Major finding: Compared with placebo, onabotulinumtoxinA 30 U approached statistical significance (P = .053) and reached significance (P less than .05 [two-sided]) at weeks 3 and 9 for changes on the Montgomery–Åsberg Depression Rating Scale.
Study details: A 24-week multicenter double-blind randomized phase 2 trial assessed the efficacy and safety of onabotulinumtoxinA versus placebo in 255 adult females with MDD.
Disclosures: This study was funded by Allergan plc. Five authors are full-time employees and one author is a former full-time employee of Allergan plc. The remaining author has received grants/royalties from and has been an advisor/consultant for multiple associations and pharmaceutical companies.
Brin MF et al. Int Clin Psychopharmacol. 2020 Jan. doi: 10.1097/YIC.0000000000000290.